Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Weekly and Monthly CAM2038 in Opioid-Dependent Subjects with Chronic Pain
NCT02710526Phase 2Completed
- Sponsor
- Braeburn Pharmaceuticals
- Start
- Feb 2015
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of buprenorphine extended-release injection in opioid use disorder (OUD), chronic pain, sponsored by Braeburn Pharmaceuticals. Started Feb 2015; status: completed.
02
Drugs
buprenorphine extended-release injection
03
Conditions
opioid use disorder (OUD)chronic pain
Beyond the preview
Go deeper on NCT02710526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02710526.